VJHemOnc shared a post on X:
“A recent subgroup analysis focused on the safety and efficacy of teclistamab in patients with R/R Multiple Myeloma with high-risk features. Luciano Costa of UAB Heersink School of Medicine provides insight into the findings.”
Source: VJHemOnc/X